Half-Life (Normalesrd) Hours
2.1/7.8-20
Plasma Protein Binding %
95
Volume Of Distribution L/Kg
0.24-0.35
Dose For Normal Renal Function
200 mg bid-qid
Second Dose
Second Dose: 400 mg SR q24h
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
50-100% [B]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
25-50% [B]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
Avoid [B]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: Avoid, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: Avoid, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Not applicable, not available
References
Goa KL, Barradell LB, Plosker GL. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia. Drugs. 1996; 52: 725-53. [PMID: 9118820] / Monk JP, Todd PA. Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs. 1987; 33: 539-76. [PMID: 3301301]